1 Report Overview 1.1 Research Scope 1.2 Market Segment by Type 1.2.1 Global Hemophilia Drugs Market Size Growth Rate by Type (2017 VS 2021 VS 2028) 1.2.2 Hemophilia A 1.2.3 Inhibitors 1.2.4 Hemophilia B 1.2.5 Von Willebrand Disease 1.3 Market Segment by Application 1.3.1 Global Hemophilia Drugs Market Share by Application (2017 VS 2021 VS 2028) 1.3.2 Recombinant Therapies 1.3.3 Plasma-Derived Therapies 1.4 Study Objectives 1.5 Years Considered 2 Market Perspective 2.1 Global Hemophilia Drugs Market Size (2017-2028) 2.1.1 Global Hemophilia Drugs Revenue (2017-2028) 2.1.2 Global Hemophilia Drugs Sales (2017-2028) 2.2 Global Hemophilia Drugs Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028 2.2.1 Global Hemophilia Drugs Sales by Regions (2017-2022) 2.2.2 Global Hemophilia Drugs Revenue by Regions (2017-2022) 2.3 Global Hemophilia Drugs Market Size Forecast by Region 2.3.1 Global Hemophilia Drugs Sales Forecast by Region (2023-2028) 2.3.2 Global Hemophilia Drugs Revenue Forecast by Region (2023-2028) 2.4 Global Top Hemophilia Drugs Regions (Countries) Ranking by Market Size 2.5 Hemophilia Drugs Market Dynamics 2.5.1 Hemophilia Drugs Market Trends 2.5.2 Hemophilia Drugs Market Drivers 2.5.3 Hemophilia Drugs Market Challenges 2.5.4 Hemophilia Drugs Market Restraints 3 Competitive Landscape by Manufacturers 3.1 Global Top Hemophilia Drugs Manufacturers by Sales (2017-2022) 3.1.1 Global Hemophilia Drugs Sales by Manufacturers (2017-2022) 3.1.2 Global Hemophilia Drugs Sales Market Share by Manufacturers (2017-2022) 3.1.3 Global 5 and 10 Largest Manufacturers by Hemophilia Drugs Sales in 2021 3.2 Global Top Manufacturers Hemophilia Drugs by Revenue 3.2.1 Global Hemophilia Drugs Revenue by Manufacturers (2017-2022) 3.2.2 Top Hemophilia Drugs Manufacturers Covered: Ranking by Revenue 3.2.3 Global Hemophilia Drugs Revenue Share by Manufacturers (2017-2022) 3.2.4 Global Hemophilia Drugs Market Concentration Ratio (CR5 and HHI) 3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hemophilia Drugs as of 2021) 3.4 Global Hemophilia Drugs Average Selling Price (ASP) by Manufacturers 3.5 Key Manufacturers Hemophilia Drugs Plants/Factories Distribution and Area Served 3.6 Date of Key Manufacturers Enter into Hemophilia Drugs Market 3.7 Key Manufacturers Hemophilia Drugs Product Offered 3.8 Mergers & Acquisitions, Expansion Plans 4 Global Hemophilia Drugs Market Size by Type 4.1 Global Hemophilia Drugs Historic Market Review by Type (2017-2022) 4.1.1 Global Hemophilia Drugs Sales Market Share by Type (2017-2022) 4.1.2 Global Hemophilia Drugs Revenue Market Share by Type (2017-2022) 4.1.3 Hemophilia Drugs Price by Type (2017-2022) 4.2 Global Hemophilia Drugs Market Estimates and Forecasts by Type (2023-2028) 4.2.1 Global Hemophilia Drugs Sales Forecast by Type (2023-2028) 4.2.2 Global Hemophilia Drugs Revenue Forecast by Type (2023-2028) 4.2.3 Hemophilia Drugs Price Forecast by Type (2023-2028) 5 Global Hemophilia Drugs Market Size by Application 5.1 Global Hemophilia Drugs Historic Market Review by Application (2017-2022) 5.1.1 Global Hemophilia Drugs Sales Market Share by Application (2017-2022) 5.1.2 Global Hemophilia Drugs Revenue Market Share by Application (2017-2022) 5.1.3 Hemophilia Drugs Price by Application (2017-2022) 5.2 Global Hemophilia Drugs Market Estimates and Forecasts by Application (2023-2028) 5.2.1 Global Hemophilia Drugs Sales Forecast by Application (2023-2028) 5.2.2 Global Hemophilia Drugs Revenue Forecast by Application (2023-2028) 5.2.3 Hemophilia Drugs Price Forecast by Application (2023-2028) 6 North America 6.1 North America Hemophilia Drugs Sales Breakdown by Company 6.1.1 North America Hemophilia Drugs Sales by Company (2017-2022) 6.1.2 North America Hemophilia Drugs Revenue by Company (2017-2022) 6.2 North America Hemophilia Drugs Market Size by Type 6.2.1 North America Hemophilia Drugs Sales by Type (2017-2028) 6.2.2 North America Hemophilia Drugs Revenue by Type (2017-2028) 6.3 North America Hemophilia Drugs Market Size by Application 6.3.1 North America Hemophilia Drugs Sales by Application (2017-2028) 6.3.2 North America Hemophilia Drugs Revenue by Application (2017-2028) 6.4 North America Hemophilia Drugs Market Size by Country 6.4.1 North America Hemophilia Drugs Sales by Country (2017-2028) 6.4.2 North America Hemophilia Drugs Revenue by Country (2017-2028) 6.4.3 U.S. 6.4.4 Canada 7 Europe 7.1 Europe Hemophilia Drugs Sales Breakdown by Company 7.1.1 Europe Hemophilia Drugs Sales by Company (2017-2022) 7.1.2 Europe Hemophilia Drugs Revenue by Company (2017-2022) 7.2 Europe Hemophilia Drugs Market Size by Type 7.2.1 Europe Hemophilia Drugs Sales by Type (2017-2028) 7.2.2 Europe Hemophilia Drugs Revenue by Type (2017-2028) 7.3 Europe Hemophilia Drugs Market Size by Application 7.3.1 Europe Hemophilia Drugs Sales by Application (2017-2028) 7.3.2 Europe Hemophilia Drugs Revenue by Application (2017-2028) 7.4 Europe Hemophilia Drugs Market Size by Country 7.4.1 Europe Hemophilia Drugs Sales by Country (2017-2028) 7.4.2 Europe Hemophilia Drugs Revenue by Country (2017-2028) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 8 Asia Pacific 8.1 Asia Pacific Hemophilia Drugs Sales Breakdown by Company 8.1.1 Asia Pacific Hemophilia Drugs Sales by Company (2017-2022) 8.1.2 Asia Pacific Hemophilia Drugs Revenue by Company (2017-2022) 8.2 Asia Pacific Hemophilia Drugs Market Size by Type 8.2.1 Asia Pacific Hemophilia Drugs Sales by Type (2017-2028) 8.2.2 Asia Pacific Hemophilia Drugs Revenue by Type (2017-2028) 8.3 Asia Pacific Hemophilia Drugs Market Size by Application 8.3.1 Asia Pacific Hemophilia Drugs Sales by Application (2017-2028) 8.3.2 Asia Pacific Hemophilia Drugs Revenue by Application (2017-2028) 8.4 Asia Pacific Hemophilia Drugs Market Size by Region 8.4.1 Asia Pacific Hemophilia Drugs Sales by Region 8.4.2 Asia Pacific Hemophilia Drugs Revenue by Region 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 India 8.4.7 Australia 8.4.8 Taiwan 8.4.9 Indonesia 8.4.10 Thailand 8.4.11 Malaysia 8.4.12 Philippines 8.4.13 Vietnam 9 Latin America 9.1 Latin America Hemophilia Drugs Sales Breakdown by Company 9.1.1 Latin America Hemophilia Drugs Sales by Company (2017-2022) 9.1.2 Latin America Hemophilia Drugs Revenue by Company (2017-2022) 9.2 Latin America Hemophilia Drugs Market Size by Type 9.2.1 Latin America Hemophilia Drugs Sales by Type (2017-2028) 9.2.2 Latin America Hemophilia Drugs Revenue by Type (2017-2028) 9.3 Latin America Hemophilia Drugs Market Size by Application 9.3.1 Latin America Hemophilia Drugs Sales by Application (2017-2028) 9.3.2 Latin America Hemophilia Drugs Revenue by Application (2017-2028) 9.4 Latin America Hemophilia Drugs Market Size by Country 9.4.1 Latin America Hemophilia Drugs Sales by Country (2017-2028) 9.4.2 Latin America Hemophilia Drugs Revenue by Country (2017-2028) 9.4.3 Mexico 9.4.4 Brazil 9.4.5 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Hemophilia Drugs Sales Breakdown by Company 10.1.1 Middle East and Africa Hemophilia Drugs Sales by Company (2017-2022) 10.1.2 Middle East and Africa Hemophilia Drugs Revenue by Company (2017-2022) 10.2 Middle East and Africa Hemophilia Drugs Market Size by Type 10.2.1 Middle East and Africa Hemophilia Drugs Sales by Type (2017-2028) 10.2.2 Middle East and Africa Hemophilia Drugs Revenue by Type (2017-2028) 10.3 Middle East and Africa Hemophilia Drugs Market Size by Application 10.3.1 Middle East and Africa Hemophilia Drugs Sales by Application (2017-2028) 10.3.2 Middle East and Africa Hemophilia Drugs Revenue by Application (2017-2028) 10.4 Middle East and Africa Hemophilia Drugs Market Size by Country 10.4.1 Middle East and Africa Hemophilia Drugs Sales by Country (2017-2028) 10.4.2 Middle East and Africa Hemophilia Drugs Revenue by Country (2017-2028) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 U.A.E 11 Company Profiles 11.1 Baxalta 11.1.1 Baxalta Corporation Information 11.1.2 Baxalta Overview 11.1.3 Baxalta Hemophilia Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.1.4 Baxalta Hemophilia Drugs Products and Services 11.1.5 Baxalta Hemophilia Drugs SWOT Analysis 11.1.6 Baxalta Recent Developments 11.2 Bayer 11.2.1 Bayer Corporation Information 11.2.2 Bayer Overview 11.2.3 Bayer Hemophilia Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.2.4 Bayer Hemophilia Drugs Products and Services 11.2.5 Bayer Hemophilia Drugs SWOT Analysis 11.2.6 Bayer Recent Developments 11.3 CSL Behring 11.3.1 CSL Behring Corporation Information 11.3.2 CSL Behring Overview 11.3.3 CSL Behring Hemophilia Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.3.4 CSL Behring Hemophilia Drugs Products and Services 11.3.5 CSL Behring Hemophilia Drugs SWOT Analysis 11.3.6 CSL Behring Recent Developments 11.4 Pfizer 11.4.1 Pfizer Corporation Information 11.4.2 Pfizer Overview 11.4.3 Pfizer Hemophilia Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.4.4 Pfizer Hemophilia Drugs Products and Services 11.4.5 Pfizer Hemophilia Drugs SWOT Analysis 11.4.6 Pfizer Recent Developments 11.5 Alnylam Pharmaceuticals 11.5.1 Alnylam Pharmaceuticals Corporation Information 11.5.2 Alnylam Pharmaceuticals Overview 11.5.3 Alnylam Pharmaceuticals Hemophilia Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.5.4 Alnylam Pharmaceuticals Hemophilia Drugs Products and Services 11.5.5 Alnylam Pharmaceuticals Hemophilia Drugs SWOT Analysis 11.5.6 Alnylam Pharmaceuticals Recent Developments 11.6 BioMarin 11.6.1 BioMarin Corporation Information 11.6.2 BioMarin Overview 11.6.3 BioMarin Hemophilia Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.6.4 BioMarin Hemophilia Drugs Products and Services 11.6.5 BioMarin Hemophilia Drugs SWOT Analysis 11.6.6 BioMarin Recent Developments 11.7 Catalyst Biosciences 11.7.1 Catalyst Biosciences Corporation Information 11.7.2 Catalyst Biosciences Overview 11.7.3 Catalyst Biosciences Hemophilia Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.7.4 Catalyst Biosciences Hemophilia Drugs Products and Services 11.7.5 Catalyst Biosciences Hemophilia Drugs SWOT Analysis 11.7.6 Catalyst Biosciences Recent Developments 11.8 Dimension Therapeutics 11.8.1 Dimension Therapeutics Corporation Information 11.8.2 Dimension Therapeutics Overview 11.8.3 Dimension Therapeutics Hemophilia Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.8.4 Dimension Therapeutics Hemophilia Drugs Products and Services 11.8.5 Dimension Therapeutics Hemophilia Drugs SWOT Analysis 11.8.6 Dimension Therapeutics Recent Developments 11.9 F. Hoffmann-La Roche 11.9.1 F. Hoffmann-La Roche Corporation Information 11.9.2 F. Hoffmann-La Roche Overview 11.9.3 F. Hoffmann-La Roche Hemophilia Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.9.4 F. Hoffmann-La Roche Hemophilia Drugs Products and Services 11.9.5 F. Hoffmann-La Roche Hemophilia Drugs SWOT Analysis 11.9.6 F. Hoffmann-La Roche Recent Developments 11.10 Grifols 11.10.1 Grifols Corporation Information 11.10.2 Grifols Overview 11.10.3 Grifols Hemophilia Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.10.4 Grifols Hemophilia Drugs Products and Services 11.10.5 Grifols Hemophilia Drugs SWOT Analysis 11.10.6 Grifols Recent Developments 11.11 Octapharma 11.11.1 Octapharma Corporation Information 11.11.2 Octapharma Overview 11.11.3 Octapharma Hemophilia Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.11.4 Octapharma Hemophilia Drugs Products and Services 11.11.5 Octapharma Recent Developments 11.12 Sangamo Biosciences 11.12.1 Sangamo Biosciences Corporation Information 11.12.2 Sangamo Biosciences Overview 11.12.3 Sangamo Biosciences Hemophilia Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.12.4 Sangamo Biosciences Hemophilia Drugs Products and Services 11.12.5 Sangamo Biosciences Recent Developments 11.13 Spark Therapeutics 11.13.1 Spark Therapeutics Corporation Information 11.13.2 Spark Therapeutics Overview 11.13.3 Spark Therapeutics Hemophilia Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.13.4 Spark Therapeutics Hemophilia Drugs Products and Services 11.13.5 Spark Therapeutics Recent Developments 11.14 Swedish Orphan Biovitrum 11.14.1 Swedish Orphan Biovitrum Corporation Information 11.14.2 Swedish Orphan Biovitrum Overview 11.14.3 Swedish Orphan Biovitrum Hemophilia Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.14.4 Swedish Orphan Biovitrum Hemophilia Drugs Products and Services 11.14.5 Swedish Orphan Biovitrum Recent Developments 12 Value Chain and Sales Channels Analysis 12.1 Hemophilia Drugs Value Chain Analysis 12.2 Hemophilia Drugs Key Raw Materials 12.2.1 Key Raw Materials 12.2.2 Raw Materials Key Suppliers 12.3 Hemophilia Drugs Production Mode & Process 12.4 Hemophilia Drugs Sales and Marketing 12.4.1 Hemophilia Drugs Sales Channels 12.4.2 Hemophilia Drugs Distributors 12.5 Hemophilia Drugs Customers 13 Research Findings and Conclusion 14 Appendix 14.1 Research Methodology 14.1.1 Methodology/Research Approach 14.1.2 Data Source 14.2 Author Details 14.3 Disclaimer

List of Tables Table 1. Global Hemophilia Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million) Table 2. Major Manufacturers of Hemophilia A Table 3. Major Manufacturers of Inhibitors Table 4. Major Manufacturers of Hemophilia B Table 5. Major Manufacturers of Von Willebrand Disease Table 6. Global Hemophilia Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million) Table 7. Global Hemophilia Drugs Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028 Table 8. Global Hemophilia Drugs Sales by Region (2017-2022) & (K Units) Table 9. Global Hemophilia Drugs Sales Market Share by Region (2017-2022) Table 10. Global Hemophilia Drugs Revenue by Region (2017-2022) & (US$ Million) Table 11. Global Hemophilia Drugs Revenue Market Share by Region (2017-2022) Table 12. Global Hemophilia Drugs Sales Forecast by Region (2023-2028) & (K Units) Table 13. Global Hemophilia Drugs Sales Market Share Forecast by Region (2023-2028) Table 14. Global Hemophilia Drugs Revenue Forecast by Region (2023-2028) & (US$ Million) Table 15. Global Hemophilia Drugs Revenue Market Share Forecast by Region (2023-2028) Table 16. Top Hemophilia Drugs Regions (Countries) Ranking by Market Size (US$ Million) in 2021 Table 17. Hemophilia Drugs Market Trends Table 18. Hemophilia Drugs Market Drivers Table 19. Hemophilia Drugs Market Challenges Table 20. Hemophilia Drugs Market Restraints Table 21. Global Hemophilia Drugs Sales by Manufacturers (2017-2022) & (K Units) Table 22. Global Hemophilia Drugs Sales Share by Manufacturers (2017-2022) Table 23. Global Hemophilia Drugs Revenue by Manufacturers (2017-2022) & (US$ Million) Table 24. Ranking of Global Top Hemophilia Drugs Manufacturers by Revenue (US$ Million) in 2021 Table 25. Hemophilia Drugs Revenue Share by Manufacturers (2017-2022) Table 26. Global Hemophilia Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) Table 27. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hemophilia Drugs as of 2021) Table 28. Key Manufacturers Hemophilia Drugs Average Selling Price (ASP) & (2017-2022) & (USD/Unit) Table 29. Key Manufacturers Hemophilia Drugs Plants/Factories Distribution Table 30. Key Manufacturers Hemophilia Drugs Area Served Table 31. Date of Key Manufacturers Enter into Hemophilia Drugs Market Table 32. Key Manufacturers Hemophilia Drugs Product Type Table 33. Mergers & Acquisitions, Expansion Plans Table 34. Global Hemophilia Drugs Sales (K Units) by Type (2017-2022) Table 35. Global Hemophilia Drugs Sales Share by Type (2017-2022) Table 36. Global Hemophilia Drugs Revenue (US$ Million) Market Share by Type (2017-2022) Table 37. Global Hemophilia Drugs Price (K Units) by Type (2017-2022) Table 38. Global Hemophilia Drugs Sales (K Units) by Type (2023-2028) Table 39. Global Hemophilia Drugs Sales Share by Type (2023-2028) Table 40. Global Hemophilia Drugs Revenue (US$ Million) Market Share by Type (2023-2028) Table 41. Global Hemophilia Drugs Revenue Share by Type (2023-2028) Table 42. Global Hemophilia Drugs Price (K Units) by Type (2023-2028) Table 43. Global Hemophilia Drugs Sales (K Units) by Application (2017-2022) Table 44. Global Hemophilia Drugs Sales Share by Application (2017-2022) Table 45. Global Hemophilia Drugs Revenue (US$ Million) Market Share by Application (2017-2022) Table 46. Global Hemophilia Drugs Price (K Units) by Application (2017-2022) Table 47. Global Hemophilia Drugs Sales (K Units) by Application (2023-2028) Table 48. Global Hemophilia Drugs Sales Share by Application (2023-2028) Table 49. Global Hemophilia Drugs Revenue (US$ Million) Market Share by Application (2023-2028) Table 50. Global Hemophilia Drugs Revenue Share by Application (2023-2028) Table 51. Global Hemophilia Drugs Price (K Units) by Application (2023-2028) Table 52. North America Hemophilia Drugs Sales by Company (2017-2022) & (K Units) Table 53. North America Hemophilia Drugs Sales Market Share by Company (2017-2022) Table 54. North America Hemophilia Drugs Revenue by Company (2017-2022) & (US$ Million) Table 55. North America Hemophilia Drugs Revenue Market Share by Company (2017-2022) Table 56. North America Hemophilia Drugs Sales by Type (2017-2022) & (K Units) Table 57. North America Hemophilia Drugs Sales by Type (2023-2028) & (K Units) Table 58. North America Hemophilia Drugs Revenue by Type (2017-2022) & (US$ Million) Table 59. North America Hemophilia Drugs Revenue by Type (2023-2028) & (US$ Million) Table 60. North America Hemophilia Drugs Sales by Application (2017-2022) & (K Units) Table 61. North America Hemophilia Drugs Sales by Application (2023-2028) & (K Units) Table 62. North America Hemophilia Drugs Revenue by Application (2017-2022) & (US$ Million) Table 63. North America Hemophilia Drugs Revenue by Application (2023-2028) & (US$ Million) Table 64. North America Hemophilia Drugs Sales by Country (2017-2022) & (K Units) Table 65. North America Hemophilia Drugs Sales by Country (2023-2028) & (K Units) Table 66. North America Hemophilia Drugs Revenue by Country (2017-2022) & (US$ Million) Table 67. North America Hemophilia Drugs Revenue by Country (2023-2028) & (US$ Million) Table 68. Europe Hemophilia Drugs Sales by Company (2017-2022) & (K Units) Table 69. Europe Hemophilia Drugs Sales Market Share by Company (2017-2022) Table 70. Europe Hemophilia Drugs Revenue by Company (2017-2022) & (US$ Million) Table 71. Europe Hemophilia Drugs Revenue Market Share by Company (2017-2022) Table 72. Europe Hemophilia Drugs Sales by Type (2017-2022) & (K Units) Table 73. Europe Hemophilia Drugs Sales by Type (2023-2028) & (K Units) Table 74. Europe Hemophilia Drugs Revenue by Type (2017-2022) & (US$ Million) Table 75. Europe Hemophilia Drugs Revenue by Type (2023-2028) & (US$ Million) Table 76. Europe Hemophilia Drugs Sales by Application (2017-2022) & (K Units) Table 77. Europe Hemophilia Drugs Sales by Application (2023-2028) & (K Units) Table 78. Europe Hemophilia Drugs Revenue by Application (2017-2022) & (US$ Million) Table 79. Europe Hemophilia Drugs Revenue by Application (2023-2028) & (US$ Million) Table 80. Europe Hemophilia Drugs Sales by Country (2017-2022) & (K Units) Table 81. Europe Hemophilia Drugs Sales by Country (2023-2028) & (K Units) Table 82. Europe Hemophilia Drugs Revenue by Country (2017-2022) & (US$ Million) Table 83. Europe Hemophilia Drugs Revenue by Country (2023-2028) & (US$ Million) Table 84. Asia Pacific Hemophilia Drugs Sales by Company (2017-2022) & (K Units) Table 85. Asia Pacific Hemophilia Drugs Sales Market Share by Company (2017-2022) Table 86. Asia Pacific Hemophilia Drugs Revenue by Company (2017-2022) & (US$ Million) Table 87. Asia Pacific Hemophilia Drugs Revenue Market Share by Company (2017-2022) Table 88. Asia Pacific Hemophilia Drugs Sales by Type (2017-2022) & (K Units) Table 89. Asia Pacific Hemophilia Drugs Sales by Type (2023-2028) & (K Units) Table 90. Asia Pacific Hemophilia Drugs Revenue by Type (2017-2022) & (US$ Million) Table 91. Asia Pacific Hemophilia Drugs Revenue by Type (2023-2028) & (US$ Million) Table 92. Asia Pacific Hemophilia Drugs Sales by Application (2017-2022) & (K Units) Table 93. Asia Pacific Hemophilia Drugs Sales by Application (2023-2028) & (K Units) Table 94. Asia Pacific Hemophilia Drugs Revenue by Application (2017-2022) & (US$ Million) Table 95. Asia Pacific Hemophilia Drugs Revenue by Application (2023-2028) & (US$ Million) Table 96. Asia Pacific Hemophilia Drugs Sales by Region (2017-2022) & (K Units) Table 97. Asia Pacific Hemophilia Drugs Sales by Region (2023-2028) & (K Units) Table 98. Asia Pacific Hemophilia Drugs Revenue by Region (2017-2022) & (US$ Million) Table 99. Asia Pacific Hemophilia Drugs Revenue by Region (2023-2028) & (US$ Million) Table 100. Latin America Hemophilia Drugs Sales by Company (2017-2022) & (K Units) Table 101. Latin America Hemophilia Drugs Sales Market Share by Company (2017-2022) Table 102. Latin America Hemophilia Drugs Revenue by Company (2017-2022) & (US$ Million) Table 103. Latin America Hemophilia Drugs Revenue Market Share by Company (2017-2022) Table 104. Latin America Hemophilia Drugs Sales by Type (2017-2022) & (K Units) Table 105. Latin America Hemophilia Drugs Sales by Type (2023-2028) & (K Units) Table 106. Latin America Hemophilia Drugs Revenue by Type (2017-2022) & (US$ Million) Table 107. Latin America Hemophilia Drugs Revenue by Type (2023-2028) & (US$ Million) Table 108. Latin America Hemophilia Drugs Sales by Application (2017-2022) & (K Units) Table 109. Latin America Hemophilia Drugs Sales by Application (2023-2028) & (K Units) Table 110. Latin America Hemophilia Drugs Revenue by Application (2017-2022) & (US$ Million) Table 111. Latin America Hemophilia Drugs Revenue by Application (2023-2028) & (US$ Million) Table 112. Latin America Hemophilia Drugs Sales by Country (2017-2022) & (K Units) Table 113. Latin America Hemophilia Drugs Sales by Country (2023-2028) & (K Units) Table 114. Latin America Hemophilia Drugs Revenue by Country (2017-2022) & (US$ Million) Table 115. Latin America Hemophilia Drugs Revenue by Country (2023-2028) & (US$ Million) Table 116. Middle East and Africa Hemophilia Drugs Sales by Company (2017-2022) & (K Units) Table 117. Middle East and Africa Hemophilia Drugs Sales Market Share by Company (2017-2022) Table 118. Middle East and Africa Hemophilia Drugs Revenue by Company (2017-2022) & (US$ Million) Table 119. Middle East and Africa Hemophilia Drugs Revenue Market Share by Company (2017-2022) Table 120. Middle East and Africa Hemophilia Drugs Sales by Type (2017-2022) & (K Units) Table 121. Middle East and Africa Hemophilia Drugs Sales by Type (2023-2028) & (K Units) Table 122. Middle East and Africa Hemophilia Drugs Revenue by Type (2017-2022) & (US$ Million) Table 123. Middle East and Africa Hemophilia Drugs Revenue by Type (2023-2028) & (US$ Million) Table 124. Middle East and Africa Hemophilia Drugs Sales by Application (2017-2022) & (K Units) Table 125. Middle East and Africa Hemophilia Drugs Sales by Application (2023-2028) & (K Units) Table 126. Middle East and Africa Hemophilia Drugs Revenue by Application (2017-2022) & (US$ Million) Table 127. Middle East and Africa Hemophilia Drugs Revenue by Application (2023-2028) & (US$ Million) Table 128. Middle East and Africa Hemophilia Drugs Sales by Country (2017-2022) & (K Units) Table 129. Middle East and Africa Hemophilia Drugs Sales by Country (2023-2028) & (K Units) Table 130. Middle East and Africa Hemophilia Drugs Revenue by Country (2017-2022) & (US$ Million) Table 131. Middle East and Africa Hemophilia Drugs Revenue by Country (2023-2028) & (US$ Million) Table 132. Baxalta Corporation Information Table 133. Baxalta Description and Overview Table 134. Baxalta Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 135. Baxalta Hemophilia Drugs Product and Services Table 136. Baxalta Hemophilia Drugs SWOT Analysis Table 137. Baxalta Recent Developments Table 138. Bayer Corporation Information Table 139. Bayer Description and Overview Table 140. Bayer Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 141. Bayer Hemophilia Drugs Product and Services Table 142. Bayer Hemophilia Drugs SWOT Analysis Table 143. Bayer Recent Developments Table 144. CSL Behring Corporation Information Table 145. CSL Behring Description and Overview Table 146. CSL Behring Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 147. CSL Behring Hemophilia Drugs Product and Services Table 148. CSL Behring Hemophilia Drugs SWOT Analysis Table 149. CSL Behring Recent Developments Table 150. Pfizer Corporation Information Table 151. Pfizer Description and Overview Table 152. Pfizer Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 153. Pfizer Hemophilia Drugs Product and Services Table 154. Pfizer Hemophilia Drugs SWOT Analysis Table 155. Pfizer Recent Developments Table 156. Alnylam Pharmaceuticals Corporation Information Table 157. Alnylam Pharmaceuticals Description and Overview Table 158. Alnylam Pharmaceuticals Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 159. Alnylam Pharmaceuticals Hemophilia Drugs Product and Services Table 160. Alnylam Pharmaceuticals Hemophilia Drugs SWOT Analysis Table 161. Alnylam Pharmaceuticals Recent Developments Table 162. BioMarin Corporation Information Table 163. BioMarin Description and Overview Table 164. BioMarin Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 165. BioMarin Hemophilia Drugs Product and Services Table 166. BioMarin Hemophilia Drugs SWOT Analysis Table 167. BioMarin Recent Developments Table 168. Catalyst Biosciences Corporation Information Table 169. Catalyst Biosciences Description and Overview Table 170. Catalyst Biosciences Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 171. Catalyst Biosciences Hemophilia Drugs Product and Services Table 172. Catalyst Biosciences Hemophilia Drugs SWOT Analysis Table 173. Catalyst Biosciences Recent Developments Table 174. Dimension Therapeutics Corporation Information Table 175. Dimension Therapeutics Description and Overview Table 176. Dimension Therapeutics Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 177. Dimension Therapeutics Hemophilia Drugs Product and Services Table 178. Dimension Therapeutics Hemophilia Drugs SWOT Analysis Table 179. Dimension Therapeutics Recent Developments Table 180. F. Hoffmann-La Roche Corporation Information Table 181. F. Hoffmann-La Roche Description and Overview Table 182. F. Hoffmann-La Roche Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 183. F. Hoffmann-La Roche Hemophilia Drugs Product and Services Table 184. F. Hoffmann-La Roche Hemophilia Drugs SWOT Analysis Table 185. F. Hoffmann-La Roche Recent Developments Table 186. Grifols Corporation Information Table 187. Grifols Description and Overview Table 188. Grifols Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 189. Grifols Hemophilia Drugs Product and Services Table 190. Grifols Hemophilia Drugs SWOT Analysis Table 191. Grifols Recent Developments Table 192. Octapharma Corporation Information Table 193. Octapharma Description and Overview Table 194. Octapharma Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 195. Octapharma Hemophilia Drugs Product and Services Table 196. Octapharma Recent Developments Table 197. Sangamo Biosciences Corporation Information Table 198. Sangamo Biosciences Description and Overview Table 199. Sangamo Biosciences Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 200. Sangamo Biosciences Hemophilia Drugs Product and Services Table 201. Sangamo Biosciences Recent Developments Table 202. Spark Therapeutics Corporation Information Table 203. Spark Therapeutics Description and Overview Table 204. Spark Therapeutics Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 205. Spark Therapeutics Hemophilia Drugs Product and Services Table 206. Spark Therapeutics Recent Developments Table 207. Swedish Orphan Biovitrum Corporation Information Table 208. Swedish Orphan Biovitrum Description and Overview Table 209. Swedish Orphan Biovitrum Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 210. Swedish Orphan Biovitrum Hemophilia Drugs Product and Services Table 211. Swedish Orphan Biovitrum Recent Developments Table 212. Key Raw Materials Lists Table 213. Raw Materials Key Suppliers Lists Table 214. Hemophilia Drugs Distributors List Table 215. Hemophilia Drugs Customers List Table 216. Research Programs/Design for This Report Table 217. Key Data Information from Secondary Sources Table 218. Key Data Information from Primary Sources List of Figures Figure 1. Hemophilia Drugs Product Picture Figure 2. Global Hemophilia Drugs Sales Market Share by Type in 2021 & 2028 Figure 3. Hemophilia A Product Picture Figure 4. Inhibitors Product Picture Figure 5. Hemophilia B Product Picture Figure 6. Von Willebrand Disease Product Picture Figure 7. Global Hemophilia Drugs Sales Market Share by Application in 2021 & 2028 Figure 8. Recombinant Therapies Use Case Figure 9. Plasma-Derived Therapies Use Case Figure 10. Hemophilia Drugs Report Years Considered Figure 11. Global Hemophilia Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 12. Global Hemophilia Drugs Market Size 2017-2028 (US$ Million) Figure 13. Global Hemophilia Drugs Sales (2017-2022) & (K Units) Figure 14. Global Hemophilia Drugs Market Size Market Share by Region: 2021 VS 2028 Figure 15. Global Hemophilia Drugs Sales Market Share by Region (2017-2022) Figure 16. Global Hemophilia Drugs Sales Market Share by Region in 2021 Figure 17. Global Hemophilia Drugs Revenue Market Share by Region in 2017 VS 2021 Figure 18. Global Hemophilia Drugs Sales Share by Manufacturers in 2021 Figure 19. The 5 and 10 Largest Manufacturers in the World: Market Share by Hemophilia Drugs Sales in 2021 Figure 20. Hemophilia Drugs Revenue Share by Manufacturers in 2021 Figure 21. Hemophilia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021 Figure 22. Global Hemophilia Drugs Revenue Share by Type (2017-2022) Figure 23. Global Hemophilia Drugs Revenue Growth Rate by Type in 2017 & 2021 Figure 24. Global Hemophilia Drugs Revenue Share by Application (2017-2022) Figure 25. Global Hemophilia Drugs Revenue Growth Rate by Application in 2017 & 2021 Figure 26. North America Hemophilia Drugs Sales Market Share by Type (2017-2028) Figure 27. North America Hemophilia Drugs Revenue Market Share by Type (2017-2028) Figure 28. North America Hemophilia Drugs Sales Market Share by Application (2017-2028) Figure 29. North America Hemophilia Drugs Revenue Market Share by Application (2017-2028) Figure 30. North America Hemophilia Drugs Sales Share by Country (2017-2028) Figure 31. North America Hemophilia Drugs Revenue Share by Country (2017-2028) Figure 32. U.S. Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 33. Canada Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 34. Europe Hemophilia Drugs Sales Market Share by Type (2017-2028) Figure 35. Europe Hemophilia Drugs Revenue Market Share by Type (2017-2028) Figure 36. Europe Hemophilia Drugs Sales Market Share by Application (2017-2028) Figure 37. Europe Hemophilia Drugs Revenue Market Share by Application (2017-2028) Figure 38. Europe Hemophilia Drugs Sales Share by Country (2017-2028) Figure 39. Europe Hemophilia Drugs Revenue Share by Country (2017-2028) Figure 40. Germany Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 41. France Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 42. U.K. Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 43. Italy Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 44. Russia Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 45. Asia Pacific Hemophilia Drugs Sales Market Share by Type (2017-2028) Figure 46. Asia Pacific Hemophilia Drugs Revenue Market Share by Type (2017-2028) Figure 47. Asia Pacific Hemophilia Drugs Sales Market Share by Application (2017-2028) Figure 48. Asia Pacific Hemophilia Drugs Revenue Market Share by Application (2017-2028) Figure 49. Asia Pacific Hemophilia Drugs Sales Share by Region (2017-2028) Figure 50. Asia Pacific Hemophilia Drugs Revenue Share by Region (2017-2028) Figure 51. China Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 52. Japan Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 53. South Korea Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 54. India Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 55. Australia Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 56. Taiwan Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 57. Indonesia Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 58. Thailand Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 59. Malaysia Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 60. Philippines Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 61. Vietnam Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 62. Latin America Hemophilia Drugs Sales Market Share by Type (2017-2028) Figure 63. Latin America Hemophilia Drugs Revenue Market Share by Type (2017-2028) Figure 64. Latin America Hemophilia Drugs Sales Market Share by Application (2017-2028) Figure 65. Latin America Hemophilia Drugs Revenue Market Share by Application (2017-2028) Figure 66. Latin America Hemophilia Drugs Sales Share by Country (2017-2028) Figure 67. Latin America Hemophilia Drugs Revenue Share by Country (2017-2028) Figure 68. Mexico Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 69. Brazil Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 70. Argentina Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 71. Middle East and Africa Hemophilia Drugs Sales Market Share by Type (2017-2028) Figure 72. Middle East and Africa Hemophilia Drugs Revenue Market Share by Type (2017-2028) Figure 73. Middle East and Africa Hemophilia Drugs Sales Market Share by Application (2017-2028) Figure 74. Middle East and Africa Hemophilia Drugs Revenue Market Share by Application (2017-2028) Figure 75. Middle East and Africa Hemophilia Drugs Sales Share by Country (2017-2028) Figure 76. Middle East and Africa Hemophilia Drugs Revenue Share by Country (2017-2028) Figure 77. Turkey Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 78. Saudi Arabia Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 79. U.A.E Hemophilia Drugs Revenue (2017-2028) & (US$ Million) Figure 80. Hemophilia Drugs Value Chain Figure 81. Hemophilia Drugs Production Process Figure 82. Channels of Distribution Figure 83. Distributors Profiles Figure 84. Bottom-up and Top-down Approaches for This Report Figure 85. Data Triangulation Figure 86. Key Executives Interviewed

Baxalta Bayer CSL Behring Pfizer Alnylam Pharmaceuticals BioMarin Catalyst Biosciences Dimension Therapeutics F. Hoffmann-La Roche Grifols Octapharma Sangamo Biosciences Spark Therapeutics Swedish Orphan Biovitrum